Trexquant Investment LP acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 12,922 shares of the medical research company’s stock, valued at approximately $1,413,000.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in Edwards Lifesciences by 6.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 564,397 shares of the medical research company’s stock valued at $61,446,000 after acquiring an additional 33,347 shares during the period. Legal & General Group Plc raised its stake in Edwards Lifesciences by 1.9% in the 3rd quarter. Legal & General Group Plc now owns 1,118,298 shares of the medical research company’s stock valued at $122,217,000 after acquiring an additional 20,931 shares during the period. Amundi Pioneer Asset Management Inc. raised its stake in Edwards Lifesciences by 0.8% in the 3rd quarter. Amundi Pioneer Asset Management Inc. now owns 690,472 shares of the medical research company’s stock valued at $75,476,000 after acquiring an additional 5,663 shares during the period. Eagle Asset Management Inc. raised its stake in Edwards Lifesciences by 4.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 446,483 shares of the medical research company’s stock valued at $49,108,000 after acquiring an additional 19,846 shares during the period. Finally, Great West Life Assurance Co. Can raised its stake in Edwards Lifesciences by 2.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 205,084 shares of the medical research company’s stock valued at $22,303,000 after acquiring an additional 4,559 shares during the period. 82.16% of the stock is owned by institutional investors.
Several research firms have weighed in on EW. Canaccord Genuity reiterated a “buy” rating and set a $155.00 price objective (up previously from $150.00) on shares of Edwards Lifesciences in a research report on Sunday, July 30th. Barclays PLC reiterated an “equal weight” rating and set a $120.00 price objective on shares of Edwards Lifesciences in a research report on Saturday, September 30th. Zacks Investment Research cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Deutsche Bank AG lowered their price objective on Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating on the stock in a research report on Thursday, October 26th. Finally, BidaskClub cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Seven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $125.17.
Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up $0.53 during midday trading on Monday, hitting $109.34. The company had a trading volume of 389,500 shares, compared to its average volume of 1,625,180. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.45. The company has a market capitalization of $23,138.53, a PE ratio of 30.29, a P/E/G ratio of 1.96 and a beta of 0.46.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The company had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. During the same quarter in the previous year, the business posted $0.68 EPS. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. research analysts anticipate that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.
In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $112.15, for a total value of $594,395.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $106.86, for a total value of $3,515,694.00. The disclosure for this sale can be found here. Insiders sold 191,440 shares of company stock worth $20,645,937 in the last 90 days. 2.13% of the stock is owned by company insiders.
WARNING: “Trexquant Investment LP Acquires Shares of 12,922 Edwards Lifesciences Corporation (EW)” was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2017/11/27/trexquant-investment-lp-acquires-shares-of-12922-edwards-lifesciences-corporation-ew.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.